Movement Disorders

Sebastian Heinzel, Daniela Berg, Thomas Gasser, Honglei Chen, Chun Yao, Ronald B. Postuma, the MDS Task Force on the Definition of Parkinson's Disease August 15, 2019

Abstract

The MDS Research Criteria for Prodromal PD allow the diagnosis of prodromal Parkinson’s disease using an evidence‐based conceptual framework, which was designed to be updated as new evidence becomes available. New prospective evidence of predictive values of risk and prodromal markers published since 2015 was reviewed and integrated into the criteria.… Read More...

Guglielmo Foffani, Inés Trigo‐Damas, José A. Pineda‐Pardo, Javier Blesa, Rafael Rodríguez‐Rojas, Raul Martínez‐Fernández, José A. Obeso August 15, 2019

Abstract

A major unmet need in Parkinson’s disease (PD) is to slow the inexorable progression of neurodegeneration. Clinical trials that evaluated promising pharmacological strategies have repeatedly failed. Nonetheless, the advent of focused ultrasound provides new opportunities toward the goal of developing a safe and effective disease‐modifying therapy for PD.… Read More...

Duncan J. McLauchlan, Thomas Lancaster, David Craufurd, David E.J. Linden, Anne E. Rosser July 31, 2019

Abstract

Background

Apathy is a deficit in goal‐directed behavior that significantly affects quality of life and function. It is common in Huntington’s disease and other disorders affecting corticostriatal pathways. Deficits in processing of reward, altered effort, and executive dysfunction are associated with apathy in other disorders, but the cognitive processes leading to apathy in Huntington’s disease remain largely unknown.… Read More...

Brit Mollenhauer, Chelsea J. Caspell‐Garcia, Christopher S. Coffey, Peggy Taylor, Andy Singleton, Leslie M. Shaw, John Q. Trojanowski, Mark Frasier, Tanya Simuni, Alex Iranzo, Wolfgang Oertel, Andrew Siderowf, Daniel Weintraub, John Seibyl, Arthur W. Toga, Caroline M. Tanner, Karl Kieburtz, Lana M. Chahine, Kenneth Marek, Douglas Galasko, for the PPMI study July 31, 2019

Abstract

Background

Aggregation of α‐synuclein is central to the pathophysiology of PD. Biomarkers related to α‐synuclein may be informative for PD diagnosis/progression.

Objectives

To analyze α‐synuclein in CSF in drug‐naïve PD, healthy controls, and prodromal PD in the Parkinson’s Progression Markers Initiative.… Read More...

Ihtsham U. Haq, Beverly M. Snively, Kathleen J. Sweadner, Cynthia K. Suerken, Jared F. Cook, Laurie J. Ozelius, Charlotte Miller, William V. McCall, Christopher Whitlow, Allison Brashear July 31, 2019

Abstract

Background and Objectives

Rapid‐onset dystonia–parkinsonism (RDP) is caused by mutations in the ATP1A3 gene, which codes for the α‐3 subunit of the Na+/K+ ATPase. It has been characterized by rapid‐onset bulbar dysfunction, limb dystonia, bradykinesia, and a rostrocaudal spatial gradient of expression, usually after a physiologic trigger.… Read More...

Maria Eleni Karakatsani, Javier Blesa, Elisa Evgenia Konofagou July 31, 2019

Abstract

Parkinson’s disease has many symptomatic treatments, but there is no neuroprotective therapy currently available. The evolution of this disease is inexorably progressive, and halting or stopping the neurodegenerative process is a major unmet need. Parkinson’s disease motor features at onset are typically limited to 1 body segment, that is, focal signs, and the nigrostriatal degeneration is highly asymmetrical and mainly present in the caudal putamen.… Read More...

Musa Ozturk, Aviva Abosch, David Francis, Jianping Wu, Joohi Jimenez‐Shahed, Nuri F. Ince July 26, 2019

Abstract

Objective

Cross‐frequency coupling has been reported in the STN of patients with PD, but its significance and functional role are still not well understood. This study investigates pharmacological modulations of subthalamic oscillations and their nonlinear cross‐frequency interactions across three consecutive cycles over unique 24‐hour‐long recordings.… Read More...

Laura Boi, Augusta Pisanu, Nigel Greig, Michael T. Scerba, David Tweedie, Giovanna Mulas, Sandro Fenu, Ezio Carboni, Saturnino Spiga, Anna R. Carta July 24, 2019

Abstract

Background

Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l‐dopa‐induced dyskinesia, a motor complication associated with l‐dopa therapy in Parkinson’s disease.… Read More...

Andoird App
Loading...